News

Sarepta Therapeutics Provides Statement on ELEVIDYS
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the ...
BioPharma Dive15m
Sarepta reports patient death in limb-girdle trial, compounding concerns on gene therapy risks
The death of a 51-year-old man in the study follows two other deaths of Duchenne patients treated with Sarepta’s marketed ...
STAT2h
Sarepta Therapeutics crisis is huge blow to Duchenne families, company
The FDA will request Sarepta Therapeutics stop all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, ...
Sarepta Stock Plummets 23%. Here’s Why.
The drop comes the day after the drugmaker said it would add a so-called black-box warning to its gene therapy Elevidys after ...
Sarepta Therapeutics Stock Plunges Over 30% In Friday Pre-Market: What's Going On
Shares of Sarepta Therapeutics (NASDAQ: SRPT) plunged 26.85% in Friday pre-market after a clinical trial participant died ...
Sarepta: Safety And Efficacy Flaws Undermine Gains On Restructuring News
Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...
Sarepta Stock Soars 30%. Why Layoffs and a ‘Black-Box’ Warning Are Good News.
Sarepta Therapeutics stock soared over 30% after the pharmaceutical company said it would lay off about 500 employees. It ...
Sarepta Therapeutics' Reorganization Boosts Investor Confidence
Sarepta agrees to FDA's black box warning and announces major restructuring, including job cuts and cost-saving measures to ...